Oct 06, 2020
Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany
May 29, 2020
Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint(TM)
May 29, 2020
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
May 07, 2020
Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences
Jan 17, 2020
Laura van 't Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
Jan 03, 2020
Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse
Nov 19, 2019
Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients
Sep 29, 2019
Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)
Jan 09, 2019
Positive Assessment Issued for Agendia's MammaPrint®
Dec 07, 2018
New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment
Dec 04, 2018
Oncology Consultants Join Agendia's FLEX Big Data Registry Study, Helping to Build a Unique Resource for Breast Cancer Research
Nov 28, 2018
Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium
Nov 14, 2018
Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients
Oct 09, 2018
Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines
Sep 25, 2018
Agendia's NGS-Based MammaPrint® BluePrint® Kit Wins Best Technological Innovation -- Diagnostics at the Medtech Insight Awards
Sep 18, 2018
Agendia and Genecast Biotechnology Partner to Launch MammaPrint® and BluePrint® in China
Aug 23, 2018
US Oncology Research Joins Agendia's FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology
Jul 25, 2018
Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations
May 01, 2018
Agendia's MammaPrint® Receives Positive Coverage Decisions from Three Major Private Healthcare Insurers